

Xaggitin XL[®] tablets: Methylphenidate prolonged release tablets for the treatment of attention deficit hyperactivity disorder (ADHD)

Cambridgeshire and Peterborough CCG recommend the following methylphenidate products for the treatment of ADHD:

- Xaggitin XL[®] prolonged release methylphenidate tablets (most cost effective prolonged release tablet option).
- Methylphenidate immediate release tablets (brand prescribing not recommended).
- Medikinet XL[®] prolonged release methylphenidate capsules.
- Equasym XL[®] prolonged release methylphenidate capsules.

Formulation should be chosen based on the individual patient's clinical condition and the patient should be maintained on this formulation (and brand if prolonged release) unless a review of current medication is required.

Medikinet XL[®] and Equasym XL[®] prolonged release **capsules** are not bioequivalent, therefore are not interchangeable with each other or any prolonged release **tablets**.

All prolonged formulations must be prescribed by BRAND.

Why Xaggitin XL[®]?

- ◆ Xaggitin XL[®] prolonged release tablets are currently the most cost effective prolonged release tablet formulation for the treatment of ADHD.
- ◆ Xaggitin XL[®] prolonged release tablets are bioequivalent to other prolonged release tablets currently available including the current market leader Concerta XL[®].
- ◆ Xaggitin XL[®] prolonged release tablets have been launched and are now the preferred brand by Cambridgeshire and Peterborough Joint Prescribing Group.
- ◆ No difference in therapeutic effect or safety profile has been identified in comparison to the other prolonged release **tablet** brands currently available.
- ◆ Last year, Cambridgeshire and Peterborough CCG could have saved an estimated £153,145 if Xaggitin XL had been prescribed where a prolonged release tablet formulation was required.

How?

- ◆ Patients should only be switched during a review or when a dose change is required. Routine switching between brands of methylphenidate is NOT advised.
- ◆ Xaggitin XL[®] is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 years of age or over. In adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood.
- ◆ Recommended as a once daily dose and is available in the same strengths as other prolonged release tablet brands.

For further information, visit www.medicines.org.uk/emc/

Information in this newsletter is believed to be accurate and true.

NHS Cambridgeshire and Peterborough CCG employees accept no liability for loss of any nature, to persons, organisations or institutions that may arise as a result of any errors or omissions.

